Plant Summary
TCMBank_ID: | TCMBANKHE005291 |
ID: | TCMBANKHE005291 |
植物拉丁名: |
|
功能与主治: | To dissipate cold and effuse exterior, relieve pain, fortify stomach, brighten eyes./Wind-cold common cold, vertex headache, generalized pain. |
药用植物名: | 香根芹 |
药用部位: | root |
TCM_ID_id: | 5121 |
化合物ID | 化合物名 | 别名 | 分子式 | 分子质量 | Smiles |
---|
TCMBANKIN005929 | 2,6-dimethoxy-p-cresol | C9H12O3 | 168.19 g/mol | CC1=CC(=C(C(=C1)OC)O)OC | |
TCMBANKIN008690 | 1-allyl-2,4-dimethoxybenzene | C11H14O2 | 178.23 g/mol | COC1=CC(=C(C=C1)CC=C)OC | |
TCMBANKIN036909 | Notoginsenoside R1 | A839906; notoginsenosider1; notoginsenoside r1 ; 2-(hydroxymethyl)-6-[2-[6-[6-(hydroxymethyl)-3-methyl-4,5-bis(oxidanyl)oxan-2-yl]oxy-4,4,8,10,14-pentamethyl-3,12-bis(oxidanyl)-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-6-methyl-hept-5-en-2-yl]oxy-oxane-3,4,5-triol; oxa; (2S,3R,4S,5S,6R)-2-[(2S)-2-[(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)-6-[(2R,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-2-yl]oxy-3,12-dihydroxy-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahyd; 80418-24-2; (2S,3R,4S,5S,6R)-2-[(1S)-1-[(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)-6-[(2R,3R,4S,5S,6R)-4,5-dihydroxy-6-methylol-3-[(2S,3R,4S,5R)-3,4,5-trihydroxytetrahydropyran-2-yl]oxy-tetrahydropyran-2-yl]oxy-3,12-dihydroxy-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15; (2S,3R,4S,5S,6R)-2-[(2S)-2-[(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)-6-[(2R,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxy-oxan-2-yl]oxy-3,12-dihydroxy-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahy; C08961; 2-[2-[6-[[4,5-dihydroxy-6-(hydroxymethyl)-3-methyl-2-oxanyl]oxy]-3,12-dihydroxy-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-6-methylhept-5-en-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol; oxane-2,3,4; (2S,3R,4S,5S,6R)-2-[(1S)-1-[(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)-6-[[(2R,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[[(2S,3R,4S,5R)-3,4,5-trihydroxy-2-tetrahydropyranyl]oxy]-2-tetrahydropyranyl]oxy]-3,12-dihydroxy-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,1; (2S,3R,4S,5S,6R)-2-[(1S)-1-[(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)-6-[(2R,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4S,5R)-3,4,5-trihydroxytetrahydropyran-2-yl]oxy-tetrahydropyran-2-yl]oxy-3,12-dihydroxy-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,1; Notoginsenoside R1 | C47H80O18 | 933 | C1([H])([H])C([H])([H])[C@](C([H])([H])[H])([C@@]([H])(C([H])([H])[C@@]([H])(O[H])[C@]([H])([C@@]([H])([C@](C([H])([H])[H])(C([H])([H])C([H])([H])\C([H])=C(/C([H])([H])[H])\C([H])([H])[H])O[C@@]2([H]) O[C@]([H])(C([H])([H])O[H])[C@@]([H])(O[H])[C@]([H])(O[H])[C@@]2([H])O[H])C([H])([H])C3([H])[H])[C@@]34C([H])([H])[H])[C@@]4(C([H])([H])[H])C([H])([H])[C@@]5([H])O[C@@]6([H])O[C@]([H])(C([H])([H])O[H] )[C@@]([H])(O[H])[C@]([H])(O[H])[C@@]6([H])O[C@@]7([H])OC([H])([H])[C@@]([H])(O[H])[C@]([H])(O[H])[C@@]7([H])O[H])[C@@]5([H])C(C([H])([H])[H])(C([H])([H])[H])[C@]1([H])O[H] |
TCMBANKIN061707 | 3,4-dimethoxyphenyl 1-o-β-d-[5-o-(3,4-di-methoxybenzoyl)]-apiofuranosyl-(1→6)-β-d-glucopyranoside | 2,4-dimethoxyphenol 1-o-β-d-[5-o-(3,4-di-methoxybenzoyl)]-apiofuranosyl-(1→6)-β-d-glucopyranoside | C28H36O15 | COC1=CC(=C(C=C1)OC2C(C(C(C(O2)COC3C(C(CO3)(COC(=O)C4=CC(=C(C=C4)OC)OC)O)O)O)O)O)OC | |
TCMBANKIN061822 | 4-methoxybenzaldehyde | KS-000002NI; EC 204-602-6; anisaldehyd; 4-methoxylbenzaldehyde; SBB040224; FEMA No. 2670; DB-012818; 4-Methoxybenzaldehyde; 4-(methyloxy)benzaldehyde; A0480; MFCD00003385; CJ-01596; SC-26765; 4-Methoxybenzaldehyde, 98% 50g; bmse010130; AK-72956; BENZALDEHYDE,4-METHOXY MFC8 H8 O2; 4-methoxybenzoyl; 4-Anisaldehyde; NCGC00257076-01; AN-22903; EBD1062; I922; P-ANISALDEHYDE; p-Anisic aldehyde; p-Methoxybenzaldehyde; Anisaldehyde; anisal; 79582-EP2305698A2; 4-methoxybenzaldehye; BG01497623; C10761; EINECS 256-891-3; DSSTox_RID_78277; Methoxybenzaldehyde (Related); EINECS 204-602-6; KB-193002; BB_NC-2206; AS02988; NSC 5590; p-Anisaldehyde, natural, 98%, FG; Benzaldehyde, 4-methoxy-; 4-Methoxy-benzaldehyde; HMS3039F08; p-Methoxybenzylidenemalonitrile; DSSTox_GSID_26997; 4-methoxybenzene carboxaldehyde; I01-0482; 123-11-5; anisic aldehyde (natural); UNII-9PA5V6656V; RP20260; AJ-14902; p-Anisaldehyde, United States Pharmacopeia (USP) Reference Standard; Q-100105; 79582-EP2292628A2; ST50213373; Anisaldehyde solution; 79582-EP2374783A1; DTXSID2026997; p-Methoxy Benzaldehyde, Natural; NCGC00090807-01; KB-115367; ZINC157146; p-Anisaldehyde, primary pharmaceutical reference standard; AI3-00223; 68894-36-0; 79582-EP2298755A1; AC-10379; AC1L1L81; CHEMBL161598; p-Anisaldehyde, for synthesis, 98.0%; 4-methoxy-benzaldehyde; LS-20018; 29578-EP2308838A1; CAS-123-11-5; SCHEMBL1100; 29578-EP2311825A1; InChI=1/C8H8O2/c1-10-8-4-2-7(6-9)3-5-8/h2-6H,1H; SMR001224521; p-Anisaldehyde, 8CI; 29578-EP2305696A2; 4-08-00-00252 (Beilstein Handbook Reference); LS-2093; 79582-EP2305695A2; para-methoxybenzaldehyde; 26249-15-0; ZRSNZINYAWTAHE-UHFFFAOYSA-N; CHEBI:28235; NATURAL ANISIC ALDEHYDE; DSSTox_CID_6997; p-Formylanisole; Anisaldehyde; p-Anisaldehyde (4-Methoxybenzaldehyde); ACMC-1BAZN; 29578-EP2305695A2; Formylanisole, p-; WLN: VHR DO1; p-Anisaldehyde, 98%; p-Methoxybenzafdehyde; BRN 0471382; ZB006571; Caswell No. 051E; ST2411506; FT-0617622; 4-Methoxybenzaldhyde; p-Anisaldehyde, certified reference material, TraceCERT(R); KSC174M6D; 29578-EP2311842A2; NCGC00259492-01; p-Methoxybenzaldehyde (natural); p-Anisaldehyde, >=97.5%, FCC, FG; p-Methoxybenzaldehyde; Tox21_303331; 721942-53-6; p-Anisic aldehyde; 3-Chlorobenzenesulfonyl chloride, 98%; 79582-EP2305696A2; MLS002152921; RTR-003659; A805017; p-Anisaldehyde, analytical standard; 4-methoxy benzaldehyde; Anis aldehyde; para-anisaldehyde; 4-methoxybezaldehyde; HSDB 2641; 29578-EP2284160A1; PubChem22535; Aubepine; 29578-EP2305698A2; Jsp001555; I01-8766; ANW-18100; 79582-EP2305697A2; AKOS000118814; 29578-EP2292628A2; M-6033; Anisic aldehyde; CTK0H4661; BR-72956; TR-003659; TRA0080347; 79582-EP2287153A1; BBL027436; Tox21_201943; NCGC00090807-02; NSC-5590; para-methoxy benzaldehyde; Obepin; CCG-214805; MolPort-000-871-198; CS-W020189; FEMA 2670; Anisaldehyde (para); 79582-EP2377841A1; 29578-EP2305697A2; MCULE-9537754812; F2190-0575; 9PA5V6656V; p-methoxy benzaldehyde; AC1Q4CCF; NSC5590; CCRIS 821; BDBM50139370; Crategine;anisaldehyde;p-Anis aldehyde;AI3-00223; 4-Anisaldehyde; Crategine; 26249-15-0; p-Methoxybenzaldehyde (natural); EINECS 204-602-6; C10761; 19486-71-6; 68894-36-0; NSC 5590; 4-Methoxybenzaldehyde-; CCRIS 821; Aubepine; ZINC00157146; InChI=1/C8H8O2/c1-10-8-4-2-7(6-9)3-5-8/h2-6H,1H; WLN: VHR DO1; Anisaldehyde solution; (4-METHOXYPHENYL)((2)H)FORMALDEHYDE; Benzaldehyde, 4-methoxy-; Benzaldehyde, methoxy-; ST5213373; p-Formylanisole; W267007_ALDRICH; HSDB 2641; A-d1; 4-08-00-00252 (Beilstein Handbook Reference); deuterio-(4-methoxyphenyl)methanone; Obepin; p-Anisaldehyde; Aub+ pine; NSC5590; ANISALDEHYDE; 4-Methoxybenzaldehyde; 97063_FLUKA; 123-11-5; FEMA No. 2670; p-Anisic aldehyde; Caswell No. 051E; BRN 0471382; 50984-52-6; DTXSID40460063; A88107_ALDRICH; 4-Methoxybenzaldehyde-alpha-d1, 98 atom % D; 4-Methoxybenzaldehyde-alpha-d1; p-Methoxybenzaldehyde; Formylanisole, p-; BENZALDEHYDE,4-METHOXY MFC8 H8 O2; LS-2093; Anisic aldehyde; EINECS 256-891-3; NCGC00090807-01; Methoxybenzaldehyde; SRA1_SIAL; p-Anisaldehyde-;p-anisaldehyde | C8H8O2 | 136.15 g/mol | COC1=CC=C(C=C1)C=O |
疾病ID | 病名 | 疾病类型 | MeSH | 参考文献 |
---|
靶点ID | 基因名 | 基因别名 | 描述 | 染色体位置 | Map_Location | 基因类型 |
---|